

To Whom it May Concern

Linz, 3. January 2020

LETTER OF INTENT

Herewith we confirm that after having reviewed the features of the product SUSPENCE™, developed by Cellex srl – Piazzale delle Belle Arti, 2 – Rome (Italy), we intend to use it in our R&D activities, particularly for further validation of our product Acto2Hem (www.actohem.com).

Acto2Hem is a product being currently developed under the EUROSTARS funding program. It is essential to the further technology development to use it also under the environment created by the SUSPENCE™ device. The planned start of our trials is March 2020.

Yours Sincerely,

Maria Seriakov



Maria Seriakov
Managing Director
M bioserviceS GmbH
Phone: +43 699 11 330 130
mailto: maria@mbioservices.com
www.mbioservices.com